For the fourth quarter ICL unit growth was up 20% year over year, including U.S. units up 109% and China units up 18%.
In China, transient COVID-related headwinds that impacted our results in the fourth quarter are subsiding as we move through the first quarter of 2023.
Our outlook for fiscal 2023 total ICL sales is approximately $340 million, which represents 26% year over year growth.
STAAR will move forward in 2023 with purpose and increased investment to further accelerate consumer awareness, surgeon confidence and adoption of our EVO ICL family of lenses, all while continuing our industry leading position as a high growth and profitable ophthalmic medical device company. #希音眼科#